CPRX CATALYST PHARMACEUTICALS, INC.

Nasdaq catalystpharma.com


$ 23.25 $ 1.56 (7.24 %)    

Tuesday, 11-Nov-2025 19:12:39 EST
QQQ $ 622.49 $ 0.90 (0.15 %)
DIA $ 479.63 $ 5.34 (1.13 %)
SPY $ 683.37 $ 2.90 (0.43 %)
TLT $ 89.91 $ 0.01 (0.01 %)
GLD $ 380.58 $ -0.09 (-0.02 %)
$ 23.1
$ 21.56
$ 21.50 x 2
$ 23.31 x 1
$ 21.52 - $ 23.12
$ 19.05 - $ 26.58
1,620,526
na
2.84B
$ 0.80
$ 13.05
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-05-2025 09-30-2025 10-Q
2 08-06-2025 06-30-2025 10-Q
3 05-07-2025 03-31-2025 10-Q
4 02-26-2025 01-01-1970 10-K
5 11-06-2024 09-30-2024 10-Q
6 08-07-2024 06-30-2024 10-Q
7 05-08-2024 03-31-2024 10-Q
8 02-28-2024 12-31-2023 10-K
9 11-08-2023 09-30-2023 10-Q
10 08-09-2023 06-30-2023 10-Q
11 05-10-2023 03-31-2023 10-Q
12 03-15-2023 12-31-2022 10-K
13 11-09-2022 09-30-2022 10-Q
14 08-09-2022 06-30-2022 10-Q
15 05-10-2022 03-31-2022 10-Q
16 03-16-2022 12-31-2021 10-K
17 11-09-2021 09-30-2021 10-Q
18 08-09-2021 06-30-2021 10-Q
19 05-10-2021 03-31-2021 10-Q
20 03-15-2021 12-31-2020 10-K
21 11-09-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-11-2020 03-31-2020 10-Q
24 03-16-2020 12-31-2019 10-K
25 11-12-2019 09-30-2019 10-Q
26 08-07-2019 06-30-2019 10-Q
27 05-10-2019 03-31-2019 10-Q
28 03-18-2019 12-31-2018 10-K
29 11-07-2018 09-30-2018 10-Q
30 08-07-2018 06-30-2018 10-Q
31 05-09-2018 03-31-2018 10-Q
32 03-14-2018 12-31-2017 10-K
33 11-08-2017 09-30-2017 10-Q
34 08-09-2017 06-30-2017 10-Q
35 05-10-2017 03-31-2017 10-Q
36 03-15-2017 12-31-2016 10-K
37 11-09-2016 09-30-2016 10-Q
38 08-09-2016 06-30-2016 10-Q
39 05-10-2016 03-31-2016 10-Q
40 03-15-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 citigroup-maintains-buy-on-catalyst-pharmaceuticals-raises-price-target-to-33

Citigroup analyst Samantha Semenkow maintains Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and raises the price target ...

 catalyst-pharmaceuticals-raises-fy2025-sales-guidance-from-545000m-565000m-to-565000m-585000m-vs-562053m-est

Catalyst Pharmaceuticals (NASDAQ:CPRX) raises FY2025 sales outlook from $545.000 million-$565.000 million to $565.000 million-$...

 catalyst-pharmaceuticals-q3-adj-eps-068-beats-033-estimate-sales-148392m-beat-136802m-estimate

Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate...

 catalyst-pharmaceuticals-reaches-settlement-with-lupin-to-delay-generic-firdapse-launch-until-2035

Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical co...

 catalyst-pharmaceuticals-affirms-fy2025-sales-guidance-of-545000m-565000m-vs-561012m-est

Catalyst Pharmaceuticals (NASDAQ:CPRX) affirms FY2025 sales outlook from $545.000 million-$565.000 million to $545.000 million-...

 catalyst-pharmaceuticals-q2-adj-eps-068-beats-038-estimate-sales-146563m-beat-140418m-estimate

Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate...

 catalyst-pharmaceuticals-applauds-nccn-guideline-update-adding-lems-diagnosis-and-amifampridine-support-for-sclc-patients

VGCC antibody testing in conjunction with neurologic consultation can diagnose LEMSAmifampridine may be considered as a support...

 catalyst-pharmaceuticals-affirms-fy2025-sales-guidance-of-54500m-56500m-vs-55724m-est

Catalyst Pharmaceuticals (NASDAQ:CPRX) affirms FY2025 sales outlook from $545.00 million-$565.00 million to $545.00 million-$56...

 catalyst-pharmaceuticals-q1-adj-eps-068-beats-053-estimate-sales-14142m-beat-13086m-estimate

Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION